Blood pressure effects of SGLT2 inhibitors make them an attractive option in diabetic patients with hypertension

J Am Soc Hypertens. 2016 Mar;10(3):186-7. doi: 10.1016/j.jash.2016.01.001.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antihypertensive Agents / therapeutic use
  • Benzhydryl Compounds / administration & dosage
  • Benzhydryl Compounds / therapeutic use
  • Blood Pressure / drug effects*
  • Blood Pressure Determination
  • Canagliflozin / therapeutic use
  • Clinical Trials, Phase III as Topic
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Glucosides / administration & dosage
  • Glucosides / therapeutic use
  • Humans
  • Hypertension / drug therapy*
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / therapeutic use*
  • Metformin / therapeutic use
  • Off-Label Use
  • Sodium-Glucose Transporter 2
  • Sodium-Glucose Transporter 2 Inhibitors*

Substances

  • 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
  • Antihypertensive Agents
  • Benzhydryl Compounds
  • Glucosides
  • Hypoglycemic Agents
  • SLC5A2 protein, human
  • Sodium-Glucose Transporter 2
  • Sodium-Glucose Transporter 2 Inhibitors
  • Canagliflozin
  • Metformin
  • empagliflozin

Associated data

  • ClinicalTrials.gov/NCT01730534